查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971573

慢性阻塞性肺病和气喘治疗设备市场：按设备类型、适应症、最终用户和分销管道划分 - 全球预测 2026-2032 年

COPD & Asthma Devices Market by Device Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年，慢性阻塞性肺病（COPD）和气喘治疗设备的市值为396.9亿美元，预计2026年将达到420.7亿美元，到2032年将达到600.8亿美元，复合年增长率为6.09%。

主要市场统计数据
基准年 2025 396.9亿美元
预计年份：2026年 420.7亿美元
预测年份 2032 600.8亿美元
复合年增长率 (%) 6.09%

本报告对该行业进行了引人入胜的概述，阐述了影响当今 COPD 和气喘管理的医疗设备的创新、临床期望和医疗保健服务压力。

随着临床需求和技术创新不断融合，呼吸设备产业正处于关键的转折点，慢性呼吸系统疾病的治疗模式也随之重塑。设备机制、气溶胶科学和数位化药物管理技术的进步，正拓展吸入和雾化系统的功能，使其不再局限于简单的药物输送，而是成为监测、个人化治疗和疗效评估的综合工具。临床医生日益需要设备收集数据，以辅助调整药物剂量、评估病情加重风险并製定远距医疗路径；而患者则希望获得关于设备易用性、便携性和正确使用方法的清晰反馈。

对改变 COPD 和气喘治疗设备在医疗保健系统中的开发、部署和整合的关键结构性变化进行详细分析。

近年来，突破性变革彻底改变了慢性阻塞性肺病（COPD）和气喘设备的研发、应用和报销方式。首先，数位化整合已从差异化因素转变为核心需求。连网吸入器、配备感测器的储雾槽以及基于云端的用药依从性平台，如今都对采购决策和临床路径产生重要影响。这种转变要求产品开发团队从设计初期就必须考虑软体生态系统、网路安全和资料互通性，并制定包含韧体更新和资料管治在内的全生命週期策略。

对 2025 年美国关税政策将如何重塑整个呼吸设备价值链的采购、生产决策和分销策略进行策略分析。

美国在2025年实施的新关税措施，使得製造商、供应商和经销商迫切需要重新评估其国际采购和贸易依赖型成本结构。为此，许多企业正在加快近岸外包步伐，推动产品重新倡议以替换受关税影响的零件，并重新谈判供应商合同，以确保在保证产品性能和合规性的同时实现盈利。这些调整并非只是权宜之计，它们会影响工程设计选择和库存管理策略，进而影响前置作业时间和生产柔软性。

透过分析设备、临床、使用者和分销环节之间的细微差异，我们可以确定产品设计和商业性重点可以创造竞争优势的领域。

细分市场分析揭示了不同设备类型、适应症、最终用户和分销管道的需求趋势、临床考虑和设计重点。按设备类型划分，重点关注干粉吸入器、定量喷雾吸入器、雾化器、缓雾吸入器以及带储雾罐和阀门的储雾罐。雾化器创新涵盖喷射式、网式和超音波式等亚型，每种类型在易用性、维护性和气溶胶性能方面各有优劣，从而影响医护人员的偏好和患者的用药依从性。根据适应症，气喘和慢性阻塞气喘(COPD) 的临床路径需要剂量计数器和呼吸作用机制等特殊功能，而某些 COPD 管理方案则更倾向于持续输注和长时间雾化。按最终用户划分，诊所、居家照护和医院环境对设备的耐用性、感染控制和维护性的要求各不相同，其中居家照护尤其需要直观的介面和远端监测支援。根据通路的不同，医院药房、线上药房和零售药房各自需要独特的包装、标籤和实施策略。此外，电子商务的兴起迫使製造商重新思考直接送药给患者、保固支援和数位支援材料。这些细分观点明确了产品差异化、临床证据和商业性执行在哪些领域最为有效。

区域比较评估：确定地理因素对临床实务、法规环境和供应链布局的影响，并分析医疗设备的采用和市场策略。

区域性研究重点在于地理因素如何影响呼吸设备的临床实践、法规环境和商业模式。在美洲，与医疗系统和支付方的谈判中，成本控制和可验证的疗效是重点，因此，能够显着提高用药依从性和减少急诊就诊的呼吸设备更受青睐。该地区主要契约製造的存在支持了本地生产和快速分销。在欧洲、中东和非洲，不同的监管环境和报销机制要求企业采取灵活的市场进入策略。对公共卫生基础设施的大量投资为支持大规模用药依从性计划和利用远端医疗进行疾病管理的呼吸设备创造了机会。在亚太地区，快速的都市化、不断成长的中产阶级和强大的本地製造能力促进了规模设计方法和具有竞争力的定价策略。同时，对数位化医疗应用的投资也推动了对互联设备和远端监测解决方案的浓厚兴趣。

对竞争与合作趋势的深入评估，定义了成熟公司、利基创新者和数位领域的新进者如何塑造呼吸设备生态系统。

慢性阻塞性肺病和气喘治疗器材领域的竞争格局呈现出多元化的格局，既有传统医疗设备製造商，也有专业吸入器开发商、电子健康技术开发商和灵活的契约製造(CMO)。老牌製造商继续利用其临床关係、监管经验和规模经济来维护现有基本客群，而专业公司则凭藉独特的性能特征、符合人体工学的设计和快速的产品改进週期展开竞争。数位健康领域的参与企业和专注于感测器技术的公司正在重新定义药物依从性测量和基于行为科学的干预措施的预期，而老牌公司则在寻求合作、授权或开发自有数位平台以保持竞争力。

优先考虑可操作的跨职能建议，将设备创新和供应链韧性转化为可持续的临床部署和商业性成果。

产业领导者应采取策略措施，将技术潜力转化为可衡量的临床和商业性成果。首先，优先考虑模组化产品架构，以实现快速组件更换和区域定制，从而降低贸易中断风险并加快监管申报。其次，投资于整合式数位化解决方案，将设备硬体与用药依从性分析和临床医生仪表板连接起来，以製定能够捕捉真实世界疗效和与支付方相关的卫生经济学终点的循证方案。第三，透过认证关键组件的多个供应商，并考虑建立区域组装基地，实现製造和采购网路多元化，从而缩短前置作业时间并提高应对力。

透过采用高度透明和严谨的混合调查方法，结合临床医生参与、监管分析和供应链映射，我们提供了切实可行的见解和建议。

本分析的调查方法结合了与关键相关人员的直接对话和全面的二手资料研究，以确保获得平衡且实用的见解。一手资料研究包括对临床医生、呼吸治疗师、采购经理、设备工程师和分销合作伙伴进行结构化访谈，以收集关于设备性能、易用性和分销渠道趋势的实际观点。这些访谈用于检验关于临床工作流程、用药依从性障碍和采购优先事项的假设，并辅以实地考察，观察设备在诊所、医院和居家医疗机构的部署。

明确的结论是：整合设备、数位化和供应链策略是决定 COPD 和气喘治疗长期成功的机制。

总而言之，受技术整合、护理模式演变以及贸易相关供应链压力的影响，慢性阻塞性肺病（COPD）和气喘治疗设备的格局正在重塑。这些设备正从单一功能的给药工具转变为慢性病照护生态系统的组成部分，这需要在产品工程、临床证据产生和商业运作之间制定协调一致的策略。数位化预期、居家照护的扩展以及区域监管差异的相互作用，带来了不同的机会和挑战。优先考虑互通性、人性化的设计和强大的製造能力的机构，将在赢得临床医生的信任和确保患者可持续获得治疗方面占据优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：慢性阻塞性肺病和气喘治疗设备市场：依设备类型划分

  • 干粉吸入器
  • 定量吸入器
  • 喷雾器
    • 喷射式雾化器
    • 网状雾化器
    • 超音波雾化器
  • 缓雾吸入器
  • 带垫片和阀门的保持腔

第九章：慢性阻塞性肺病和气喘治疗设备市场：依适应症划分

  • 气喘
  • COPD

第十章：慢性阻塞性肺病和气喘治疗设备市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十一章：慢性阻塞性肺病和气喘治疗设备市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：慢性阻塞性肺病和气喘治疗设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：慢性阻塞性肺病和气喘治疗设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：慢性阻塞性肺病和气喘治疗设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国慢性阻塞性肺病与气喘治疗设备市场

第十六章：中国慢性阻塞性肺病与气喘治疗设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Ltd.
  • Fisher & Paykel Healthcare Corporation Limited
  • GlaxoSmithKline plc
  • Novartis International AG
  • OMRON Corporation
  • PARI Medical Holding GmbH
  • ResMed Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-535C62918B2C

The COPD & Asthma Devices Market was valued at USD 39.69 billion in 2025 and is projected to grow to USD 42.07 billion in 2026, with a CAGR of 6.09%, reaching USD 60.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 39.69 billion
Estimated Year [2026] USD 42.07 billion
Forecast Year [2032] USD 60.08 billion
CAGR (%) 6.09%

A compelling industry overview that situates device innovation, clinical expectations, and healthcare delivery pressures shaping COPD and asthma management today

The respiratory device landscape is at a pivotal inflection point, driven by converging clinical priorities and technological innovation that together redefine care delivery for chronic respiratory diseases. Advances in device mechanics, aerosol science, and digital adherence technologies are expanding the functional role of inhalation and nebulization systems beyond simple drug delivery to becoming integrated tools for monitoring, personalization, and outcomes measurement. Clinicians increasingly expect devices to support data capture that informs titration, exacerbation risk assessment, and remote care pathways, while patients demand ease of use, portability, and clear feedback on correct technique.

At the same time, healthcare systems face mounting pressure to improve cost-effectiveness and patient outcomes, prompting procurement and clinical leaders to weigh device performance against total cost of care and real-world effectiveness. This environment favors interoperable solutions and partnerships that bridge device manufacturers, pharmaceutical sponsors, and digital health providers. As a result, manufacturers are prioritizing human-centered design, regulatory robustness, and evidence generation to demonstrate adherence benefits and clinical impact, while payers and providers seek measurable improvements in utilization and disease control. In this context, the executive audience must balance near-term operational imperatives with long-term investments that position products as clinically relevant, digitally enabled tools in chronic respiratory care.

An in-depth synthesis of the critical structural shifts transforming COPD and asthma device development, adoption, and health system integration

The last several years have produced transformative shifts that alter how devices for COPD and asthma are developed, adopted, and reimbursed. First, digital integration has moved from a differentiator to a core expectation; connected inhalers, sensor-enabled spacers, and cloud-based adherence platforms now influence purchasing decisions and clinical pathways. This shift compels product teams to consider software ecosystems, cybersecurity, and data interoperability from the earliest design stages, and to adopt lifecycle strategies that include firmware updates and data governance.

Second, patient-centered care models and the expansion of home-based management have elevated the importance of device portability, simplicity, and remote monitoring capabilities. Consequently, device form factors and usability testing receive greater emphasis during development cycles, and clinical validation increasingly incorporates real-world evidence collected outside traditional clinic settings. Third, supply chain resilience and component sourcing have become strategic priorities as manufacturers diversify suppliers and pursue modular designs to mitigate disruptions. Fourth, regulatory authorities are refining guidance around combination products and digital health components, encouraging incremental evidence generation tied to safety and clinical performance. Collectively, these shifts foster closer collaboration across medical device engineering, clinical affairs, regulatory, and commercial teams, and demand that organizations adopt integrated roadmaps that synchronize product, data, and market access strategies.

A strategic analysis of how 2025 United States tariff policies have reshaped sourcing, production decisions, and distribution strategies across respiratory device value chains

The introduction of new tariff measures in the United States in 2025 has created a sustained strategic imperative for manufacturers, suppliers, and distributors to reassess international sourcing and trade-dependent cost structures. In response, many organizations have accelerated nearshoring efforts, redesign initiatives to substitute tariff-exposed components, and renegotiated supplier contracts to preserve margins while maintaining product performance and regulatory compliance. These adjustments are not simply transactional; they drive engineering design choices and inventory management policies that affect lead times and production flexibility.

Additionally, procurement teams are recalibrating vendor evaluation criteria to include trade risk and total landed cost, and contract manufacturers are positioning themselves as partners that can offer geographically diversified footprint options. For some device segments, particularly those that rely on precision polymers, microfluidic assemblies, or imported electronic sensors, the tariff environment has intensified efforts to localize final assembly or to validate alternative qualified suppliers. Downstream, distributors and pharmacy channels are adapting their pricing strategies and promotional tactics to offset increased acquisition costs while preserving patient access through co-pay support programs and payer negotiations. Ultimately, the cumulative impact of tariff policy has elevated supply chain strategy to a board-level consideration, requiring cross-functional coordination among R&D, procurement, quality, and commercial teams to safeguard continuity of care and maintain competitive positioning.

A nuanced breakdown of device, clinical, user, and distribution segment dynamics that reveals where product design and commercial focus will drive competitive advantage

Segment-level insights reveal differentiated demand dynamics, clinical considerations, and design priorities across device types, indications, end users, and distribution channels. Based on device type, attention is focused on Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer, Soft Mist Inhaler, and Spacer And Valved Holding Chamber, with nebulizer innovation spanning Jet Nebulizer, Mesh Nebulizer, and Ultrasonic Nebulizer subtypes; each category presents distinct usability, maintenance, and aerosol performance trade-offs that influence clinician preference and patient adherence. Based on indication, the clinical pathways for Asthma and COPD require tailored device features, such as dose counters and breath-actuated mechanisms for asthma versus sustained-delivery or long-duration nebulization options favored in certain COPD management scenarios. Based on end user, clinic, home care, and hospital settings impose divergent requirements for device robustness, infection control, and serviceability, with home care particularly driving needs for intuitive interfaces and remote monitoring support. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each demand specific packaging, labeling, and fulfillment strategies, and the rising prominence of e-commerce is prompting manufacturers to rethink direct-to-patient logistics, warranty handling, and digital support materials. Together, these segmentation lenses clarify where product differentiation, clinical evidence, and commercial execution will be most impactful.

A comparative regional assessment revealing how geographic clinical practices, regulatory regimes, and supply chain footprints influence device adoption and market approaches

Regional insights underscore how geography shapes clinical practices, regulatory environments, and commercial models for respiratory devices. In the Americas, health systems and payer negotiations often emphasize cost containment and demonstrable outcomes, which rewards devices that yield measurable adherence improvements and reduced acute care utilization, while the presence of major contract manufacturers in the region supports localized production and rapid distribution. In Europe, Middle East & Africa, diverse regulatory pathways and heterogeneous reimbursement landscapes necessitate adaptive market access strategies, and the region's emphasis on public health infrastructure creates opportunities for devices that support large-scale adherence programs and telehealth-enabled disease management. In the Asia-Pacific region, rapid urbanization, expanding middle-class demand, and robust local manufacturing capabilities encourage design-for-scale approaches and competitive pricing, while investments in digital health adoption drive strong interest in connected devices and remote monitoring solutions.

Across all regions, local clinical guidelines, procurement norms, and patient preferences influence adoption patterns, and manufacturers that tailor product features, evidence generation strategies, and channel partnerships to each regional context will be better positioned to capture clinical trust and commercial traction. Moreover, cross-border regulatory harmonization initiatives and regional trade agreements present both opportunities and constraints that must be navigated carefully to optimize market entry and post-market support.

An insightful evaluation of competitive forces and collaboration trends that define how established firms, niche innovators, and digital entrants are shaping the respiratory device ecosystem

Competitive dynamics in the COPD and asthma device space reflect a mix of legacy medical device manufacturers, specialized inhaler innovators, electronic health technology developers, and agile contract manufacturers. Established manufacturers continue to leverage clinical relationships, regulatory experience, and scale to defend installed bases, while specialized firms compete on niche performance features, ergonomic design, and rapid iteration cycles. Digital health entrants and sensor-focused companies are reshaping expectations for adherence measurement and behaviorally informed interventions, prompting incumbents to pursue partnerships, licensing agreements, or in-house digital platform development to remain relevant.

Contract manufacturing and service providers have become strategic collaborators, offering capabilities in regulatory-compliant assembly, sterilization, and aftermarket servicing that enable original equipment manufacturers to focus on core product differentiation. Innovation is increasingly concentrated at the intersections of materials science, aerosol engineering, and embedded electronics, and intellectual property strategies now encompass both mechanical innovations and software-related algorithms. For commercial leaders, competitive advantage will hinge on the ability to demonstrate clinical value, integrate digital services, and scale manufacturing with resilient supply chains, while preserving agility to respond to regulatory guidance and payer expectations.

A pragmatic set of prioritized, cross-functional recommendations designed to convert device innovation and supply resilience into sustained clinical adoption and commercial performance

Industry leaders should adopt strategic moves that translate technological potential into measurable clinical and commercial outcomes. First, prioritize modular product architectures that allow for rapid component substitution and regional customization, thereby reducing exposure to trade disruptions and enabling faster regulatory filings. Second, invest in integrated digital solutions that pair device hardware with adherence analytics and clinician-facing dashboards, and design evidence-generation plans that capture real-world effectiveness and health-economic endpoints relevant to payers. Third, diversify manufacturing and supplier networks by qualifying multiple sources for critical components and by exploring regional assembly centers to shorten lead times and improve responsiveness.

Fourth, deepen collaborations with healthcare providers and pharmacy channels to embed devices within care pathways and to pilot value-based contracting models that align incentives around improved disease control. Fifth, enhance post-market support through scalable service models for maintenance, training, and remote troubleshooting, which will increase device longevity and patient satisfaction. Sixth, align regulatory and clinical affairs teams early in product development to ensure that digital and combination product claims are supported by appropriate evidence and documentation. By executing these steps in concert, organizations can strengthen resilience, accelerate adoption, and demonstrate the clinical and economic value necessary for durable market success.

A transparent and rigorous mixed-methods research approach combining clinician engagement, regulatory analysis, and supply chain mapping to ground practical insights and recommendations

The research methodology underpinning this analysis blends primary stakeholder engagement with comprehensive secondary synthesis to ensure balanced, actionable insights. Primary research included structured interviews with clinicians, respiratory therapists, procurement leaders, device engineers, and distribution partners to capture frontline perspectives on device performance, usability, and channel dynamics. These conversations informed hypothesis testing around clinical workflows, adherence barriers, and procurement priorities, and were complemented by site visits to observe device deployment in clinic, hospital, and home care settings.

Secondary research comprised a targeted review of peer-reviewed clinical literature, regulatory guidance documents, device safety communications, patent filings, and trade publications to validate technical assertions and to map emerging regulatory trends. Supply chain mapping and component sourcing analysis used customs and trade data alongside supplier disclosures to evaluate geographic exposures and mitigation strategies. Evidence synthesis prioritized triangulation across data sources, and methodological rigor was maintained through iterative validation with subject matter experts, ensuring that conclusions reflect practical realities and operational constraints.

A decisive conclusion that synthesizes how integrated device, digital, and supply chain strategies will determine long-term success in COPD and asthma care

In summary, the COPD and asthma device landscape is being reshaped by technological integration, shifting care models, and trade-related supply chain pressures. Devices are transitioning from single-function delivery tools to integrated components of chronic care ecosystems, demanding coordinated strategies across product engineering, clinical evidence generation, and commercial operations. The confluence of digital expectations, home-based care expansion, and regional regulatory nuances creates differentiated opportunities and challenges; organizations that prioritize interoperability, human-centered design, and resilient manufacturing will be better equipped to capture clinical trust and ensure sustained patient access.

Looking ahead, success will depend less on isolated product attributes and more on the ability to deliver measurable health outcomes through combined hardware, software, and service offerings. By aligning R&D priorities with payer and provider needs, diversifying supply chains, and forging partnerships that bridge technology and clinical practice, stakeholders can navigate current headwinds and unlock long-term value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COPD & Asthma Devices Market, by Device Type

  • 8.1. Dry Powder Inhaler
  • 8.2. Metered Dose Inhaler
  • 8.3. Nebulizer
    • 8.3.1. Jet Nebulizer
    • 8.3.2. Mesh Nebulizer
    • 8.3.3. Ultrasonic Nebulizer
  • 8.4. Soft Mist Inhaler
  • 8.5. Spacer And Valved Holding Chamber

9. COPD & Asthma Devices Market, by Indication

  • 9.1. Asthma
  • 9.2. COPD

10. COPD & Asthma Devices Market, by End User

  • 10.1. Clinic
  • 10.2. Home Care
  • 10.3. Hospital

11. COPD & Asthma Devices Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. COPD & Asthma Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. COPD & Asthma Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. COPD & Asthma Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States COPD & Asthma Devices Market

16. China COPD & Asthma Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. AstraZeneca plc
  • 17.7. Boehringer Ingelheim GmbH
  • 17.8. Chiesi Farmaceutici S.p.A.
  • 17.9. Cipla Ltd.
  • 17.10. Fisher & Paykel Healthcare Corporation Limited
  • 17.11. GlaxoSmithKline plc
  • 17.12. Novartis International AG
  • 17.13. OMRON Corporation
  • 17.14. PARI Medical Holding GmbH
  • 17.15. ResMed Inc.
  • 17.16. Sandoz International GmbH
  • 17.17. Sanofi S.A.
  • 17.18. Teva Pharmaceutical Industries Ltd.
  • 17.19. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COPD & ASTHMA DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COPD & ASTHMA DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY JET NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY JET NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY JET NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY MESH NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY MESH NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY MESH NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SPACER AND VALVED HOLDING CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SPACER AND VALVED HOLDING CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SPACER AND VALVED HOLDING CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)